Home LiteratureArticle Details
PMID: 15505275 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA

Abstract

Currently available clinical and molecular prognostic factors provide an imperfect assessment of prognosis for patients with epithelial ovarian cancer (EOC). In this study, we investigated whether tumor transcription profiling could be used as a prognostic tool in this disease. Tumor tissue from 68 patients was profiled with oligonucleotide microarrays. Samples were randomly split into training and validation sets. A three-step training procedure was used to discover a statistically significant Kaplan-Meier split in the training set. The resultant prognostic signature was then tested on an independent validation set for confirmation. In the training set, a 115-gene signature referred to as the Ovarian Cancer Prognostic Profile (OCPP) was identified. When applied to the validation set, the OCPP distinguished between patients with unfavorable and favorable overall survival (median, 30 months v not yet reached, respectively; log-rank P = .004). The signature maintained independent prognostic value in multivariate analysis, controlling for other known prognostic factors such as age, stage, grade, and debulking status. The hazard ratio for death in the unfavorable OCPP group was 4.8 (P = .021 by Cox proportional hazards analysis). The OCPP is an independent prognostic determinant of outcome in EOC. The use of gene profiling may ultimately permit identification of EOC patients appropriate for investigational treatment approaches, based on a low likelihood of achieving prolonged survival with standard first-line platinum-based therapy.

MeSH Terms
Adult Aged Biomarkers, Tumor/metabolism Biopsy, Needle Chemotherapy, Adjuvant Combined Modality Therapy DNA, Complementary/analysis Female Gene Expression Regulation, Neoplastic Genetic Predisposition to Disease Humans Immunohistochemistry Middle Aged Neoplasm Staging Neoplasms, Glandular and Epithelial/genetics,mortality,pathology,therapy Ovarian Neoplasms/genetics,mortality,pathology,therapy Ovariectomy/methods Predictive Value of Tests Prognosis RNA, Neoplasm/analysis Risk Assessment Sensitivity and Specificity Survival Analysis Treatment Outcome
Chemicals
Biomarkers, Tumor DNA, Complementary RNA, Neoplasm
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Spentzos Dimitrios
Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Levine Douglas A
Ramoni Marco F
Joseph Marie
Gu Xuesong
Boyd Jeff
Libermann Towia A
Cannistra Stephen A
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
0732-183X
Published
2004-12-01
Epub
2004-00-25
Pages
4700-10
Language
English
Region
United States
NLM ID
8309333
Subset
IM
Grants
NCI NIH HHS · R01 CA85467 · United States
NCI NIH HHS · U01 CA88175 · United States
NIDDK NIH HHS · U24 DK58739 · United States
Corrections
ErratumIn
-
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]